Proteome Sciences (GB:PRM) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Proteome Sciences PLC has reported a surge in customer engagement and service inquiries in 2024, including a significant contract from a US biopharmaceutical company. The firm is optimistic about returning to growth this year, bolstered by the launch of new proteomics services and expansion in the US. Proteome Sciences specializes in proteomics services for drug discovery and biomarker identification, with proprietary technologies like SysQuant® and TMT®MS2.
For further insights into GB:PRM stock, check out TipRanks’ Stock Analysis page.